- Report
- May 2024
- 140 Pages
Global
From €4427EUR$4,949USD£3,893GBP
- Report
- January 2024
- 206 Pages
Global
€4469EUR$4,995USD£3,929GBP
- Report
- June 2022
- 925 Pages
Global
From €2237EUR$2,500USD£1,966GBP
- Report
- December 2022
- 162 Pages
Global
From €1789EUR$2,000USD£1,573GBP
- Report
- December 2022
- 157 Pages
Global
From €1789EUR$2,000USD£1,573GBP
- Report
- December 2022
- 82 Pages
Global
From €1789EUR$2,000USD£1,573GBP
- Report
- November 2022
- 504 Pages
Global
From €2237EUR$2,500USD£1,966GBP
- Report
- November 2022
- 155 Pages
Global
From €1789EUR$2,000USD£1,573GBP
- Report
- October 2022
- 195 Pages
Global
From €1789EUR$2,000USD£1,573GBP
- Report
- September 2024
- 93 Pages
Global
From €3500EUR$4,191USD£3,185GBP
- Report
- August 2024
- 99 Pages
Global
From €3500EUR$4,191USD£3,185GBP
- Report
- July 2024
- 93 Pages
Global
From €3500EUR$4,191USD£3,185GBP
- Report
- February 2024
- 118 Pages
Global
From €3500EUR$4,191USD£3,185GBP

BeiGene is a market within the context of Oncology Drugs, which are drugs used to treat cancer. These drugs are used to target and destroy cancer cells, while minimizing damage to healthy cells. BeiGene is a biopharmaceutical company that develops and commercializes innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company focuses on developing therapies that target cancer cells with precision and accuracy, while also providing a safe and effective treatment for patients. BeiGene's portfolio includes a range of drugs, including small molecules, antibodies, and other biologics. The company also has a pipeline of novel therapies in development.
BeiGene is one of many companies in the Oncology Drugs market. Other companies include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more